vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report)'s stock price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $19.68 and traded as high as $26.97. vTv Therapeutics shares last traded at $26.97, with a volume of 3,777 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised shares of vTv Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, March 14th.
Get Our Latest Report on vTv Therapeutics
vTv Therapeutics Stock Performance
The stock has a market capitalization of $81.16 million, a price-to-earnings ratio of -2.68 and a beta of 0.56. The company has a 50 day moving average of $20.03 and a 200 day moving average of $14.71.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in vTv Therapeutics stock. Pathstone Family Office LLC bought a new stake in vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 242,937 shares of the biotechnology company's stock, valued at approximately $116,000. Pathstone Family Office LLC owned about 0.23% of vTv Therapeutics as of its most recent filing with the Securities & Exchange Commission. 17.51% of the stock is owned by institutional investors.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes that is in Phase III clinical trial; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases, psoriasis, COPD, and Atopic Dermatitis that is in Phase III clinical trial.
Read More
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
